Medical devices manufacturer Boston Scientific has secured approval from the US Food and Drug Administration (FDA) for its Precision Montage magnetic resonance imaging (MRI) spinal cord stimulator (SCS) system.


Precision Montage system provides customized relief to patients with chronic pain, in addition to offering safe access to full body MRI in a 1.5 Tesla environment when conditions of use are met.

The system features MultiWave technology, which allows delivery of multiple waveforms, including burst and higher rates. The technology will enable the system to respond to changes in pain over time.

It also features three-dimensional anatomy-driven computer model, Illumina 3D algorithm, which will help physicians to treat chronic pain.

Boston Scientific neuromodulation president and senior vice president Maulik Nanavaty said: "The Precision Montage MRI SCS System is a key addition to our Illumina 3D portfolio, offering patients more choices to manage and personalize their therapy.

"This important advancement underscores our commitment to meet the individual needs of chronic pain patients."

The company is exhibiting the Precision Montage system at the eighth World Congress of the World Institute of Pain in New York City, US, which is being held from 20 to 23 May.

Boston Scientific also produces Precision Spectra system that will provide a wide coverage for pain with 32 contacts, as well as the smallest high-capacity non-rechargeable device Precision Novi system.

In April, Boston Scientific received FDA approval for its ImageReady MR-conditional pacing system to treat bradycardia, a condition in which the heart beats too slowly.

Image: Precision Montage system offers safe access to full body magnetic resonance imaging (MRI) in a 1.5 Tesla environment. Photo: courtesy of Boston Scientific Corporation.